Biotech stocks are heating up in 2026 as GLP-1 weight loss drugs, obesity and diabetes treatments, Alzheimer’s research, neurodegenerative breakthroughs, gene editing, CRISPR, and next-gen cell therapy reshape healthcare—here are 7 biotech stocks to watch for growth, upside, and major catalysts.
1 extracted signal · 0 resolved · 1 still active
MarketBeatIndependent analyst profile- Source published
- 18 Jan 2026, 05:56 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
AI-generated source summary
Viking Therapeutics (VKTX) is presented as a compelling alternative investment in the GLP-1 market. Although currently a pre-revenue entity, VKTX demonstrated robust performance in 2025. The company's pipeline includes both injectable and oral formulations of VK2735 for obesity, with the subcutaneous version in Phase 3 trials and the oral version having completed Phase 2a. Additionally, VK2809 for MASH has completed Phase 2b trials, and VK0214 for X-ALD is also in development. These programs are supported by positive clinical trial results, emphasizing a data-driven development approach. The current price for VKTX is $33.68. The analysis posits a bullish outlook, projecting significant upside towards a target of $46.34 for 2026, driven by its robust product pipeline and strong trial outcomes. An invalidation point for this analysis is identified at $19.00. The underlying thesis suggests VKTX could become an attractive acquisition target if its upcoming clinical trials continue to yield impressive results.
AI-generated summary based on the source content.
Signal outcomes at a glance
Tracking LiveSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Live evaluation in progress
1 signal remains active.
MarketBeat
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.